Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Old API Wind-down Ltd - Ordinary Shares ARLZQ

Healthcare Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic
"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven


OTCPK:ARLZQ - Post by User

Old API Wind-down Ltd - Ordinary Shares > Institutional buyer or Fund @ $5.50 US
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by kuatoliveson Sep 07, 2016 10:31am
82 Views
Post# 25213591

RE:RE:RE:RE:RE:RE:RE:Institutional buyer or Fund @ $5.50 US

RE:RE:RE:RE:RE:RE:RE:Institutional buyer or Fund @ $5.50 US
I just assume everyone's a crook or stupid; makes planning life easier.

Wish they'd released sales figures for this one. I assume they are in the 10-15M range as that would make sense for both Merck to cut the drug loose (not worth their time) and for ARLZ to pick it up as it now gives their sales reps 3 cardio drugs to push in the US when they hit the road (Yosprala (assuming approval), Fibricor, and Zontivity.  The timing of the deal was a win as they have Yosprala pending approval to backstop any negative sentiment. End of Q3/Q4 should start seeing some appreciable revenue growth. Shall see.....
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities